title: High-dose chemotherapy with peripheral blood progenitor cell support for patients with non-small cell lung cancer: the experience of the European Group for Bone Marrow Transplantation (EBMT) Solid Tumours Working Party.
abstract: We report the experience of the EBMT Solid Tumours Working Party (STWP) using high-dose chemotherapy (HDCT) with PBPC support in patients with non-small cell lung cancer (NSCLC). Between 1989 and 2004, 36 NSCLC patients (27 men and 9 women), median age 53.5 years (range: 24-62) were treated with 63 HDCT courses. A high-dose carboplatin-based regimen was used in 53% of the cases. Thirty-two patients had relapsed/metastatic disease, while four classified as stage IIIB received HDCT followed by radiotherapy. No treatment-related death occurred. Of 25 patients who were planned to receive multi-cycle HDCT, 4 cases (16%) interrupted the treatment early due to prolonged severe toxicities and 4 (16%) due to progressive disease. Of 36 evaluable patients, 3 (8%) achieved a complete remission and 13 (36%) had a partial remission at an overall response rate of 44%. Of these, one patient with stage IIIB and one with stage IV are alive disease free at 71+ and 149+ months, respectively. After a median follow-up of 48 months (range: 6-149), median survival was 7 months (range: 1-149). Despite one anecdotal case, HDCT did not show significant activity, but induced relevant morbidity in NSCLC patients.
authors.affiliation: Istituto Oncologico Romagnolo-Santa Maria delle Croci Hospital, Ravenna, Italy. ugo_degiorgi@yahoo.com
authors.forename: U
authors.initials: U
authors.lastname: De Giorgi
authors.forename: D
authors.initials: D
authors.lastname: Blaise
authors.forename: A
authors.initials: A
authors.lastname: Lange
authors.forename: P
authors.initials: P
authors.lastname: Viens
authors.forename: M
authors.initials: M
authors.lastname: Marangolo
authors.forename: A
authors.initials: A
authors.lastname: Madroszyk
authors.forename: M
authors.initials: M
authors.lastname: Brune
authors.forename: B V
authors.initials: BV
authors.lastname: Afanassiev
authors.forename: G
authors.initials: G
authors.lastname: Rosti
authors.forename: T
authors.initials: T
authors.lastname: Demirer
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003131:Combined Modality Therapy / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005060:Europe; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects; D012042:Registries; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D016190:Carboplatin